Biologically Active Small Molecules

A fluorescent affinity probe for amyloid-&beta.

A fluorescent affinity probe for amyloid-&beta.

A fluorescent affinity probe for amyloid-&beta.

An internal standard for the quantification of creatinine by GC- or LC-MS.

An internal standard for the quantification of creatinine by GC- or LC-MS.

An internal standard for the quantification of creatinine by GC- or LC-MS.

An internal standard for the quantification of creatinine by GC- or LC-MS.

An orally bioavailable, selective inhibitor of PDGFR&alpha, PDGFR&beta, and FLT3 (IC₅₀s = 11, 3.2, and 4 nM, respectively) also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal

An orally bioavailable, selective inhibitor of PDGFR&alpha, PDGFR&beta, and FLT3 (IC₅₀s = 11, 3.2, and 4 nM, respectively) also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal

An orally bioavailable, selective inhibitor of PDGFR&alpha, PDGFR&beta, and FLT3 (IC₅₀s = 11, 3.2, and 4 nM, respectively) also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal

An orally bioavailable, selective inhibitor of PDGFR&alpha, PDGFR&beta, and FLT3 (IC₅₀s = 11, 3.2, and 4 nM, respectively) also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal

A potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC₅₀ = 8 nM) and ALK (IC₅₀ = 20 nM) receptor tyrosine kinases shows antitumor efficacy in multiple tumor models implanted in athymic mice